Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient

https://doi.org/10.4081/monaldi.2019.1023

Authors

  • Ana Hecimovic | anahecimovic1978@gmail.com Department for Lung Diseases, University Hospital Centre Zagreb, Croatia.
  • Andrea Vukic Dugac Department for Lung Diseases, University Hospital Centre Zagreb; School of Medicine, University of Zagreb, Croatia.
  • Mateja Jankovic Makek Department for Lung Diseases, University Hospital Centre Zagreb; School of Medicine, University of Zagreb, Croatia.
  • Maja Cikes School of Medicine, University of Zagreb; Department of Cardiology, University Hospital Centre Zagreb, Croatia.
  • Miroslav Samarzija Department for Lung Diseases, University Hospital Centre Zagreb; School of Medicine, University of Zagreb, Croatia.
  • Marko Jakopovic Department for Lung Diseases, University Hospital Centre Zagreb; School of Medicine, University of Zagreb, Croatia.

Abstract

Lung cancer incidence in heart transplant patients is higher than in general population and correlates with smoking history. EGFR-mutations are more frequent in adenocarcinoma and among non-smoking women but incidence in solid organ transplanted patients is still not known. We present case of a 65-year-old ex-smoker male with history of heart transplantation and EGFR positive metastatic lung adenocarcinoma. At admission he was in a severe clinical condition and treatment with erlotinib was started. Initially he had good clinical and radiologic response to treatment with only grade 1 side effects.  Data about drug interactions between cyclosporine and erlotinib are insufficient but we have to take this interaction into consideration during treatment because both drugs are substrates and inhibitors of CYP34A. In our case erlotinib was safe and well tolerated drug, there were no relevant toxicity, but close monitoring and dose reduction of cyclosporine was needed.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2019-05-30
Info
Issue
Section
Pneumology - Case Reports
Keywords:
lung cancer, EGFR mutation, heart transplantation, tyrosine kinase inhibitor, erlotinib
Statistics
  • Abstract views: 914

  • PDF: 498
How to Cite
Hecimovic, Ana, Andrea Vukic Dugac, Mateja Jankovic Makek, Maja Cikes, Miroslav Samarzija, and Marko Jakopovic. 2019. “Treatment of EGFR Positive Lung Adenocarcinoma in a Heart Transplanted Patient”. Monaldi Archives for Chest Disease 89 (2). https://doi.org/10.4081/monaldi.2019.1023.

Most read articles by the same author(s)